Poliovirus Vaccine Live Oral

Summary

Poliovirus Vaccine Live Oral (CHEMBL2108778) is a phase-3 clinical-stage vaccine component; indicated across 4 conditions including severe acute respiratory syndrome and poliomyelitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• Indications: 4 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108778
Name	Poliovirus Vaccine Live Oral
Type	Vaccine component
Max phase	3

Also known as: Poliovirus vaccine live oral, POLIOVIRUS VACCINE LIVE ORAL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
poliomyelitis	2	MONDO:0017373	EFO:0007450
malaria	1	MONDO:0005136	EFO:0001068

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).